Context There is uncertainty regarding the most appropriate criteria for recruitment,
monitoring, and reclassification in active surveillance (AS) protocols for localised prostate …

Background Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and
69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer …

Simple Summary Life expectancy in Western countries and East Asian countries has
incremented over the past decades, resulting in a rapidly aging world, while in general …

Randomized clinical trials are critical for evaluating the safety and efficacy of interventions in
oncology and informing regulatory decisions, practice guidelines, and health policy. Patient …

In the last years, the widespread use of the prostate-specific antigen (PSA) blood
examination to triage patients who will enter the diagnostic/therapeutic path for prostate …

Prostate cancer is the one of the most dominant cancer among males. It represents one of
the leading cancer death causes worldwide. Due to the current evolution of artificial …

Localized Prostate Cancer - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …

Aims Focal therapy treats individual areas of tumour in non-metastatic prostate cancer in
patients unsuitable for active surveillance. The aim of this work was to evaluate the cost …

Objectives The European Randomized Study of Screening for Prostate Cancer found that
prostate-specific antigen (PSA) screening reduced prostate cancer mortality, however the …

Prostate cancer represents the most encountered urinary malignancy in males over 50 years
old, and the second most diagnosed after lung cancer globally. Digital rectal examination …